ELVN — Enliven Therapeutics, Inc.
6 mentions in the last 24 hours · 0.02% of all mentions
Why people talked about ELVN (2026-11-06)
- Enliven Therapeutics reported Q3 2026 financial results, beating EPS estimates by $0.09.
- The company posted a GAAP EPS of -$0.36 against an estimate of -$0.46.
- Revenue was reported as $0 with no analyst estimate published for this metric.
| Bluesky | 2 | community |
| GDELT | 2 | news |
| RSS Bundle | 1 | news |
| SEC EDGAR 8-K | 1 | filings |